Literature DB >> 32232578

HR-HPV viral load quality detection provide more accurate prediction for residual lesions after treatment: a prospective cohort study in patients with high-grade squamous lesions or worse.

Lihua Chen1, Binhua Dong2, Qiaoyu Zhang1, Xiaodan Mao2, Wenyu Lin2, Guanyu Ruan2, Yafang Kang2, Pengming Sun3,4.   

Abstract

The relationship between high-risk-human-papillomavirus (HR-HPV) viral loads and residual/recurrence lesion is uncertain. This study aimed to evaluate the clinical value of HR-HPV viral loads to predict the residual/recurrence lesions among women with high-grade squamous lesions or worse (≥ HSIL) after surgery. Finally, 301 women who underwent primary screening of cervical cancer using polymerase-chain-reaction-(PCR)-reverse-dot-blot-(RDB) human papillomavirus (HPV) genotyping and cytology assays were enrolled. They received surgery and took HR-HPV viral loads with a BioPerfectus Multiplex Real-Time PCR assay. Colposcopy biopsies were performed in patients with HPV-16/18(+) and/or TCT ≥ ASCUS with HR-HPV(+). The risk of HR-HPV viral loads and potentials factors for residual/recurrence lesions were analyzed and the optimal cut-off values of HR-HPV viral loads were calculated. The significant differences were found in residual/recurrence lesions among patients with different ages, margin status, cytology and HR-HPV at 6 months (all P < 0.05). Interestingly, HPV viral loads were observed significant differences in the group of residual lesions, not recurrence group. Furthermore, except for HPV-31/33, the viral loads of HP-16/52/58 were significant differences in residual lesions. The cut-off level of HR-HPV viral loads was 5.22 copies/10,000 cells, providing viable triage for the risk of residual lesions. Compared with different follow-up methods, the HR-HPV viral loads ≥ 5.22copies/10,000 cells (HR 3.39, 95% CI 1.57-7.35) had a higher risk for developing residual lesions. HR-HPV viral loads can be a reliable predictor of residual lesions. Furthermore, women with viral loads ≥ 5.22 copies/10,000 cells may have higher risk for residual disease and should be give a more aggressive treatment and follow-up strategy.

Entities:  

Keywords:  Cervical intraepithelial neoplasia grade 2 or worse; Follow-up; Human papillomavirus; Residual or recurrence lesions; Viral loads

Year:  2020        PMID: 32232578     DOI: 10.1007/s12032-020-01363-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

1.  Risk factors predicting residual disease in subsequent hysterectomy following conization for cervical intraepithelial neoplasia (CIN) III and microinvasive cervical cancer.

Authors:  Jeong-Yeol Park; Seung Mi Lee; Chong Woo Yoo; Sokbom Kang; Sang-Yoon Park; Sang-Soo Seo
Journal:  Gynecol Oncol       Date:  2007-06-19       Impact factor: 5.482

2.  Evaluation of the impact of screening for cancer of the cervix.

Authors:  A B Miller
Journal:  IARC Sci Publ       Date:  1986

Review 3.  Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.

Authors:  Marc Arbyn; Charles W E Redman; Freija Verdoodt; Maria Kyrgiou; Menelaos Tzafetas; Sadaf Ghaem-Maghami; Karl-Ulrich Petry; Simon Leeson; Christine Bergeron; Pekka Nieminen; Jean Gondry; Olaf Reich; Esther L Moss
Journal:  Lancet Oncol       Date:  2017-11-07       Impact factor: 41.316

Review 4.  Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia.

Authors:  William Patrick Soutter; Peter Sasieni; Theo Panoskaltsis
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

5.  Application of bethesda system for cervical cytology in unhealthy cervix.

Authors:  Indu Verma; Veena Jain; Tejinder Kaur
Journal:  J Clin Diagn Res       Date:  2014-09-20

6.  Diagnostic value of human papillomavirus (HPV) 16 and HPV18 viral loads for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV.

Authors:  Michel Segondy; Jean Ngou; Helen Kelly; Tanvier Omar; Olga Goumbri-Lompo; Sylviane Doutre; Philippe Mayaud; Marie-Noelle Didelot
Journal:  J Clin Virol       Date:  2018-01-16       Impact factor: 3.168

7.  Factors affecting outcome after incomplete excision of cervical intraepithelial neoplasia.

Authors:  E Paraskevaidis; S N Kalantaridou; M Paschopoulos; K Zikopoulos; E Diakomanolis; N Dalkalitsis; G Makrydimas; L Pappa; V Malamou-Mitsi; N J Agnantis
Journal:  Eur J Gynaecol Oncol       Date:  2003       Impact factor: 0.196

8.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

9.  HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice.

Authors:  M Origoni; P Cristoforoni; S Costa; L Mariani; P Scirpa; A Lorincz; M Sideri
Journal:  Ecancermedicalscience       Date:  2012-06-18

Review 10.  Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis.

Authors:  Karoliina Tainio; Antonios Athanasiou; Kari A O Tikkinen; Riikka Aaltonen; Jovita Cárdenas; Sivan Glazer-Livson; Maija Jakobsson; Kirsi Joronen; Mari Kiviharju; Karolina Louvanto; Sanna Oksjoki; Riikka Tähtinen; Seppo Virtanen; Pekka Nieminen; Maria Kyrgiou; Ilkka Kalliala
Journal:  BMJ       Date:  2018-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.